Synthesis and Relaxometric Studies of a Dendrimer-Based pH-Responsive MRI Contrast Agent

Department of Chemistry, University of Texas at Dallas, Richardson, TX 75083, USA.
Chemistry (Impact Factor: 5.73). 08/2008; 14(24):7250-8. DOI: 10.1002/chem.200800402
Source: PubMed


The design of effective pH responsive MRI contrast agents is a key goal in the development of new diagnostic methods for conditions such as kidney disease and cancer. A key factor determining the effectiveness of an agent is the difference between the relaxivity of the "on" state compared to that of the "off" state. In this paper, we demonstrate that it is possible to improve the pH-responsive action of a low molecular weight agent by conjugating it to a macromolecular construct. The synthesis of a bifunctional pH responsive agent is reported. As part of that synthetic pathway we examine the Ing-Manske reaction, identifying an undesirable by-product and establishing effective conditions for promoting a clean and effective reaction. Reaction of the bifunctional pH responsive agent with a G5-PAMAM dendrimer yielded a product with an average of 96 chelates per dendrimer. The relaxivity of the dendrimer conjugate rises from 10.8 mM(-1) s(-1) (pH 9) to 24.0 mM(-1) s(-1) (pH 6) per Gd(3+) ion. This more than doubles the relaxivity pH response, Deltar(1), of our agent from just 51 % for the original low molecular weight chelate to 122 % for the dendrimer.

Download full-text


Available from: James C Fettinger, Apr 11, 2014
17 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic resonance imaging (MRI) has become a prominent imaging technique in medicine. Gadoliniumbased contrast agents are extensively used to enhance the contrast between normal and diseased tissues through MRI scans. The article illustrates the paramount significance of such contrast agents in MRI applications. Clinically approved contrast agents as well as those in trial period are discussed. Important parameters, i.e. hydration number, rotational correlation time, and mean residence lifetime, influencing the relaxivity (sensitivity) of such agents are described in detail. Various approaches towards relaxivity enhancement are discussed with appropriate examples from the recent literature. A decrease in the Gdwater proton distance results in significant relaxivity enhancement. A comprehensive classification and explanation of Gd3+-based contrast agents are presented. Each class is explained with suitable examples. The stability of contrast agents is dependent on their chemical structure. Future contrast agents need to be tissue specific of high relaxivity, low toxicity, and lower administered dose for in vivo use.
    Journal of Structural Chemistry 02/2013; 54(1). DOI:10.1134/S002247661301037X · 0.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic resonance imaging (MRI) has inherent advantages in safety, three-dimensional output, and clinical relevance when compared with optical and radiotracer imaging methods. However, MRI contrast agents are inherently less sensitive than agents used in other imaging modalities primarily because MRI agents are detected indirectly by changes in either the water proton relaxation rates (T(1), T(2), and T(*)(2)) or water proton intensities (chemical exchange saturation transfer and paramagnetic chemical exchange saturation transfer, CEST and PARACEST). Consequently, the detection limit of an MRI agent is determined by the characteristics of the background water signal; by contrast, optical and radiotracer-based methods permit direct detection of the agent itself. By virtue of responding to background water (which reflects bulk cell properties), however, MRI contrast agents have considerable advantages in "metabolic" imaging, that is, spatially resolving tissue variations in pH, redox state, oxygenation, or metabolite levels. In this Account, we begin by examining sensitivity limits in targeted contrast agents and then address contrast agents that respond to a physiological change; these responsive agents are effective metabolic imaging sensors. The sensitivity requirements for a metabolic imaging agent are quite different from those for a targeted Gd(3+)-based T(1) agent (for example, sensing cell receptors). Targeted Gd(3+) agents must have either an extraordinarily high water proton relaxivity (r(1)) or multiple Gd(3+) complexes clustered together at the target site on a polymer platform or nanoparticle assembly. Metabolic MRI agents differ in that the high relaxivity requirement, although helpful, is eased because these agents respond to bulk properties of tissues rather than low concentrations of a specific biological target. For optimal sensing, metabolic imaging agents should display a large change in relaxivity (deltar(1)) in response to the physiological or metabolic parameter of interest. Metabolic imaging agents have only recently begun to appear in the literature and only a few have been demonstrated in vivo. MRI maps of absolute tissue pH have been obtained with Gd(3+)-based T(1) sensors. The requirement of an independent measure of agent concentration in tissues complicates these experiments, but if qualitative changes in tissue pH are acceptable, then these agents can be quite useful. In this review, we describe examples of imaging extracellular pH in brain tumors, ischemic hearts, and pancreatic islets with Gd(3+)-based pH sensors and discuss the potential of CEST and PARACEST agents as metabolic imaging sensors.
    Accounts of Chemical Research 04/2009; 42(7):948-57. DOI:10.1021/ar800237f · 22.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A noninvasive assay that tracks the relative in vivo pharmacokinetics of two nanoparticles may accelerate the development of nanoparticles for biomedical applications, and may provide a method to select personalized nanomedicines for individual patients. To develop an in vivo competitive assay, two MRI contrast agents that could be selectively detected through paramagnetic chemical exchange saturation transfer (PARACEST) were conjugated to a second generation and fifth generation polyamidoamine (PAMAM) dendrimer. The CEST effects of each agent was calibrated relative to concentration. The effects of T(1) relaxivities of these dendritic PARACEST magnetic resonance imaging (MRI) contrast agents were found to be negligible relative to their CEST effects with respect to changes in image contrast, which facilitated the measurement of the ratios of their chemical exchange lifetimes. Injection of both contrast agents into a mouse model of mammary carcinoma resulted in a temporal increase in the CEST effect from each agent in the flank tumor. Although the in vivo CEST effects could not be used to determine the absolute concentrations of each agent within the tumor, the ratio of the in vivo CEST effects was used to measure the ratio of the concentrations of the agents. This result demonstrated that the relative in vivo pharmacokinetics of two nanoparticles may be evaluated using PARACEST MRI.
    Molecular Pharmaceutics 04/2009; 6(5):1409-16. DOI:10.1021/mp900040u · 4.38 Impact Factor
Show more